Royalty Pharma plc (RPRX)
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Royalty Pharma: 2025 Financial Performance And Strategic Outlook
Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerged as a major growth engine, surpassing traditional royalties in announced transaction value and offering structural advantages for biopharma funding.
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View
Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns.
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated
Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust FCF, portfolio growth, and a diversified royalty-based business model. Platform model delivering diversified biopharma exposure, buybacks ongoing, and new deals to be priced in. Our buy is then confirmed.
Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript
Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Marshall Urist - Executive Vice President of Research & Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Terence Flynn - Morgan Stanley, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma Third Quarter Earnings Conference Call.
Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago.
